Alterity Therapeutics (PRNAD) Equity Ratio (2015 - 2025)

Alterity Therapeutics (PRNAD) has reported Equity Ratio for 11 consecutive years, with 4.91 the latest figure, recorded in Q2 2025.

• In Q2 2025, Equity Ratio fell 581.52% year-over-year to 4.91; the TTM figure through Jun 2025 stood at 4.91 (down 581.52% YoY), while the FY2025 annual figure was 4.91, up 55.95% from the prior year.
• Equity Ratio came in at 4.91 for Q2 2025 at Alterity Therapeutics, down from 1.02 in the prior quarter.
• The five-year high for Equity Ratio was 55.81 in Q2 2023, with the low at 4.91 in Q2 2025.
• Average Equity Ratio over 5 years is 10.74, with a median of 0.91 recorded in 2021.
• Across the five-year window, Equity Ratio surged 6408.97% in 2023 and sank 581.52% in 2025, its largest moves.
• Year by year, Equity Ratio stood at 0.91 in 2021, then slipped by 5.48% to 0.86 in 2022, then surged by 6408.97% to 55.81 in 2023, then slumped by 98.17% to 1.02 in 2024, then sank by 581.52% to 4.91 in 2025.
• According to Business Quant data, Equity Ratio over the past three periods registered 4.91, 1.02, and 55.81 for Q2 2025, Q2 2024, and Q2 2023 respectively.